BioGaia ABBGLAF 100 Peter Lynch Fair Value is $3.45 as of Jul. 04, 2026, which is 33% above its 10-year median of 2.60. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.52 (Fairly Valued). The stock has 5 warning signs investors should review. Among 265 Drug Manufacturers companies, BioGaia AB ranks worse than 81.51% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, BioGaia AB's PEG is 1. BioGaia AB's 5-Year TTM EBITDA Growth Rate is 9.89.
BioGaia AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35. Therefore, the Peter Lynch Fair Value for today is $3.45.
As of today (2026-07-04), BioGaia AB's share price is $12.20. BioGaia AB's Peter Lynch fair value is $3.45. Therefore, BioGaia AB's Price to Peter Lynch Fair Value Ratio for today is 3.53.
The historical rank and industry rank for BioGaia AB's Peter Lynch Fair Value or its related term are showing as below:
BGLAF'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.8 Med: 2.6 Max: 9.32
Current: 2.71
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of BioGaia AB was 9.32. The lowest was 1.80. And the median was 2.60.
BGLAF's Price-to-Peter-Lynch-Fair-Value is ranked worse than 81.51% of 265
companies
in the Drug Manufacturers industry
Industry Median: 1.31
vs BGLAF: 2.71
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
BioGaia AB (OTCPK:BGLAF) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 9.89 instead of 15 in this case.
BioGaia AB's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
12.20
/
3.45
=
3.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB Peter Lynch Fair Value Related Terms
BioGaia AB Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLAF vs ZTS, UTHR: Peter Lynch Fair Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Price-to-Peter-Lynch-Fair-Value falls into.
BioGaia AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
BioGaia AB (BGLAF) has a Peter Lynch Fair Value of $3.45 as of Jul. 04, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on BioGaia AB and its competitors. This is 33% above median its historical median of 2.60. Over the past decade, BioGaia AB's Peter Lynch Fair Value has ranged from 1.80 to 9.32. According to the industry distribution chart, BioGaia AB ranks #216 out of 265 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is BioGaia AB's Peter Lynch Fair Value too high?
BioGaia AB's current Peter Lynch Fair Value of $3.45 is 33% above median its 10-year median of 2.60. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 9.32. The Drug Manufacturers industry median Peter Lynch Fair Value is 1.31. BioGaia AB's value of $3.45 is 163.4% above this industry median. Based on the distribution chart, BioGaia AB ranks #216 out of 265 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Peter Lynch Fair Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #216 out of 265 companies for Peter Lynch Fair Value. This places BioGaia AB in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.31. BioGaia AB's value of $3.45 is 163.4% above this benchmark. Historically, BioGaia AB's own Peter Lynch Fair Value has ranged from 1.80 to 9.32 over the past decade. While the company's 10-year median is 2.60 vs. the industry median of 1.31, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.31, based on 265 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Peter Lynch Fair Value of $3.45 is 163.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Peter Lynch Fair Value is $3.45, which is 33% above median its own 10-year median of 2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.52, compared to a current price of $12.20 — trading 2.6% below its estimated fair value. The current Peter Lynch Fair Value is $3.45, which is 33% above median its 10-year median of 2.60 and 163.4% above the Drug Manufacturers industry median of 1.31. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Peter Lynch Fair Value is $3.45 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 2.6% below its estimated GF Value™ of $12.52.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Peter Lynch Fair Value: $3.45 (33% above median its 10-year median of 2.60)
GF Value™: $12.52 vs. price of $12.20 (2.6% below fair value)
Industry Position: 163.4% above the Drug Manufacturers median (#216 of 265)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
